Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter I Croucher

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Nature Reviews. Cancer|June 4, 2020
The dormant cancer cell life cycleTri Giang Phan, Peter I Croucher
Cancer Research|March 5, 2003
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cellsClaire M Shipman, Peter I Croucher
Bone|December 15, 2010
Bisphosphonates in preclinical bone oncologyPhilippe Clézardin, Ismahène Benzaïd, Peter I Croucher
Blood|December 24, 2005
ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrinAbdullah Karadag, Min Zhou, Peter I Croucher
Calcified Tissue International|September 19, 2013
Signaling between tumor cells and the host bone marrow microenvironmentNatasa Kovacic, Peter I Croucher, Michelle M McDonald
Nature Reviews. Cancer|May 26, 2016
Bone metastasis: the importance of the neighbourhoodPeter I Croucher, Michelle M McDonald, T John Martin
Cold Spring Harbor Perspectives in Medicine|September 25, 2019
Cancer Cell Dormancy in MetastasisMatthew A Summers, Michelle M McDonald, Peter I Croucher
Bone|July 10, 2010
Tumor-host cell interactions in the bone disease of myelomaJessica A Fowler, Claire M Edwards, Peter I Croucher
The Journal of Biological Chemistry|August 19, 2007
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathwaysSrdjan Vitovski, Jennifer S Phillips, Jon Sayers, et al.
Cancer|January 28, 2003
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone diseasePeter I Croucher, Claire M Shipman, Ben Van Camp, et al.
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Nature Reviews. Cancer|June 4, 2020
The dormant cancer cell life cycleTri Giang Phan, Peter I Croucher
Cancer Research|March 5, 2003
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cellsClaire M Shipman, Peter I Croucher
Bone|December 15, 2010
Bisphosphonates in preclinical bone oncologyPhilippe Clézardin, Ismahène Benzaïd, Peter I Croucher
Blood|December 24, 2005
ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrinAbdullah Karadag, Min Zhou, Peter I Croucher
Calcified Tissue International|September 19, 2013
Signaling between tumor cells and the host bone marrow microenvironmentNatasa Kovacic, Peter I Croucher, Michelle M McDonald
Nature Reviews. Cancer|May 26, 2016
Bone metastasis: the importance of the neighbourhoodPeter I Croucher, Michelle M McDonald, T John Martin
Cold Spring Harbor Perspectives in Medicine|September 25, 2019
Cancer Cell Dormancy in MetastasisMatthew A Summers, Michelle M McDonald, Peter I Croucher
Bone|July 10, 2010
Tumor-host cell interactions in the bone disease of myelomaJessica A Fowler, Claire M Edwards, Peter I Croucher
The Journal of Biological Chemistry|August 19, 2007
Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathwaysSrdjan Vitovski, Jennifer S Phillips, Jon Sayers, et al.
Cancer|January 28, 2003
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone diseasePeter I Croucher, Claire M Shipman, Ben Van Camp, et al.
Pageof 11